SEED Therapeutics Announces Poster Presentation at AACR Annual Meeting 2026

KING OF PRUSSIA, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company specializing in molecular glue degraders, today announced that it will have a poster presentation at the 2026 Annual Meeting of the American Association for Cancer Research ("AACR"), taking place on April 17 through 22, 2026 in San Diego, California.

Presentation Details:

Title: RBM39 Degrader Anticancer Activity Against Neuroblastoma; MYC and CDKN2A/B as Potential Response Biomarkers
Presenter / Authors: James Finn, Imad Salhab, Haihong Jin, Fei Liu, Dong Liu, Yunkai Zhang, Xing Liu, James Tonra, Lan Huang, Dan Lu
Presentation Time: April 21, 2026, 2PM to 5PM PT
Location: Poster Section 15 at San Diego Convention Center
Session Category: Experimental and Molecular Therapeutics
Session Title: Proximity-Induced Drug Discovery 2
Poster Board Number: 12
Poster Number: 5785

About SEED Therapeutics
SEED Therapeutics is a clinical-stage biotechnology company pioneering rationally designed molecular glue degraders to treat diseases driven by undruggable proteins. Its proprietary RITE3™ platform enables targeted protein degradation with small-molecule precision.

SEED Therapeutics was co-founded by four scientific leaders:

Nobel Laureate Prof. Avram Hershko, discoverer of the ubiquitin-proteasome system
Dr. Lan Huang, solved the first E3 Ligase structure and a serial biotech entrepreneur
Prof. Ning Zheng (University of Washington, HHMI Investigator), pioneer of RING-finger E3 Ligase structures and coined the term “molecular glue”
Prof. Michele Pagano (NYU Grossman School of Medicine, HHMI Investigator), a preeminent expert on E3 ligase biology

Eli Lilly and Co. and Eisai Co., Ltd., are cornerstone investors and research collaborators, supporting SEED’s mission to unlock undruggable disease targets. The company’s pipeline includes six molecular glue programs across oncology, neurodegeneration, immunology, and virology.

Media & Investor Contact
IR@seedtherapeutics.com
PR@seedtherapeutics.com
www.seedtherapeutics.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.